IDXX Quote, Financials, Valuation and Earnings

Haemonetics has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 9.79%. IDEXX Laboratories's return on equity of 57.37% beat Haemonetics's return on equity of 13.51%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.16%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 50.77%. Given that Haemonetics has higher upside potential than IDEXX Laboratories, analysts believe Haemonetics is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $975.5M, which are larger than Haemonetics quarterly revenues of $345.5M. IDEXX Laboratories's net income of $232.8M is higher than Haemonetics's net income of $33.8M. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.43x while Haemonetics's PE ratio is 30.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.11x versus 2.78x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 14.25%. IDEXX Laboratories's return on equity of 57.37% beat Insulet's return on equity of 49.55%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.16%. On the other hand Insulet has an analysts' consensus of $292.29 which suggests that it could grow by 5.98%. Given that IDEXX Laboratories has higher upside potential than Insulet, analysts believe IDEXX Laboratories is more attractive than Insulet.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $975.5M, which are larger than Insulet quarterly revenues of $543.9M. IDEXX Laboratories's net income of $232.8M is higher than Insulet's net income of $77.5M. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.43x while Insulet's PE ratio is 47.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.11x versus 10.62x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 36.03%. IDEXX Laboratories's return on equity of 57.37% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.16%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,005.61 which suggests that it could grow by 47.55%. Given that Regeneron Pharmaceuticals has higher upside potential than IDEXX Laboratories, analysts believe Regeneron Pharmaceuticals is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. IDEXX Laboratories's net income of $232.8M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.43x while Regeneron Pharmaceuticals's PE ratio is 16.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.11x versus 5.67x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 28.56%. IDEXX Laboratories's return on equity of 57.37% beat Zoetis's return on equity of 48%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.16%. On the other hand Zoetis has an analysts' consensus of $210.66 which suggests that it could grow by 26.99%. Given that Zoetis has higher upside potential than IDEXX Laboratories, analysts believe Zoetis is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Zoetis has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.852%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.04% to investors and pays a quarterly dividend of $0.43 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Zoetis pays out 29.52% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Zoetis quarterly revenues of $2.4B. IDEXX Laboratories's net income of $232.8M is lower than Zoetis's net income of $682M. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.43x while Zoetis's PE ratio is 31.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.11x versus 8.29x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.